Sarepta's Q2 Earnings: $13M Profit Showed Up, but the $1.2B–$1.3B Guidance Is the Real Story

Q2 profit improved the balance sheet, but guidance kept the commercial debate alive

This report is the first notable test of Michael Severino's execution after his July 27, 2026 appointment as CEO. Sarepta's answer was mixed: Q2 GAAP operating income of $13 million shows the company can post a profitable quarter, yet the forward guidance still suggests the commercial engine is not yet running at full speed.

That is the tension in the release. A profitable quarter is encouraging, but investors still need evidence that site activity, enrollment, and infusion momentum are building quickly enough to support the 2026 guide and set up growth into 2027.

Sarepta narrowed 2026 net product revenue guidance to $1.2 billion-$1.3 billion, expects second-half revenue to be modestly below the first half, and says ELEVIDYS revenue is likely lower in the third quarter. For now, that leaves the short-term case more cautious than confident.

The demand signal is improving, but the revenue payoff still looks delayed

Portfolio breadth is not the same as stronger demand

Sarepta's story is no longer just ELEVIDYS. Product revenue also includes PMO, and the company markets four approved Duchenne therapies. That matters because a broader portfolio can expand treatment activity or simply divide the same patient population across more options.

There is at least some encouraging commercial activity. Management said ELEVIDYS enrollment-form activity improved sequentially, with more engagement from returning sites and interest from new referral sites. That looks like a better field story than Sarepta has had in recent quarters.

Why the timing still favors caution

The key issue is lag. Sarepta said the typical approximately six-month enrollment-to-infusion timeline delays the revenue impact, and management said improving enrollment forms may contribute more meaningfully in 2027. In other words, the early signs may be improving, but the revenue proof still looks more like a 2027 story than a Q2 story.

There is also a mix issue. Sarepta raised collaboration and other revenue guidance to $550 million-$600 million, mainly because of higher Roche contract-manufacturing revenue. That helps total revenue and funding flexibility, but it is not the same as stronger demand for the company's own medicines.

Side evidence is still relevant. Early siRNA data and the submissions seeking traditional approval for AMONDYS 45 and VYONDYS 53 are supportive signs, but they do not settle the main near-term question: whether the Duchenne business is accelerating now or asking investors to wait.

What matters most under the new leadership team

The profitable quarter and the cash build matter, but mainly because they give the new team more time to execute. After July 27, 2026, when Michael Severino became CEO, the better test of execution is whether optimism at the site and field level is turning into reported demand-not just how comfortable the balance sheet looks while that happens. Even with cash and investments increased by approximately $197 million to $945 million, this still looks like a show-me story.

The next signals to watch

• Whether ELEVIDYS enrollment activity continues improving quarter over quarter
• Whether that activity begins translating into revenue within the expected roughly six-month enrollment-to-infusion window
• Whether the 2026 product-revenue range holds, narrows again, or ultimately gets upgraded
• Whether PMO and ELEVIDYS carry more of the load as management hopes

The leadership change may bring tighter commercial execution, but the market still needs repeated proof, not just one strong operating quarter. For now, Sarepta looks less like a finished rerating story than a business that needs demand to catch up with the positive framing.